Company / Cash & Equivalents
Zai Lab Ltd Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$679.6M
FY2025
5-year range
$442.1M / $964.1M
FY2021-FY2025
Trend
+51.1%
vs FY2024
Sector context
#30 of 207
Health Care
What the data says
Zai Lab Ltd's cash & equivalents of $680M is higher than 86% of companies in the Health Care sector (FY2025). Cash & Equivalents returned to growth in FY2025 after 2 years of decline, reaching $680M.
Based on SEC 10-K filings.
$680M in FY2025 with a 5-year CAGR of +55.0%. Top quartile in the Health Care sector.
Declined from $790M to $680M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -11.0%
- 5-Year CAGR
- +55.0%
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 207This company $679.6M Sector average $669.5M
▼
+1.5% above sector average
Key checks
Key Insights
- 5-year CAGR of +55.0%, indicating consistent growth.
- In FY2025, cash & equivalents increased 51.1% year-over-year.
- Ranks #30 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.09 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $679.6M | +51.1% |
| FY2024 | $449.7M | -43.1% |
| FY2023 | $790.2M | -18.0% |
| FY2022 | $964.1M | +118.1% |
| FY2021 | $442.1M | +482.3% |
| FY2020 | $75.9M | +0.0% |
| FY2019 | $75.9M | +20.6% |
| FY2018 | $63.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026